DeepMed Research

SWOG

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1956-01-01

Employees: 101

Market Cap: -

Website: http://www.swog.org

Clinical Trials

S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Biological: cetuximab
Drug: irinotecan hydrochloride
Drug: vemurafenib

First Posted Date: 2014-06-17

Last Posted Date: 2020-12-30

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 106

Registration Number: NCT02164916

Locations: 🇺🇸
Toledo Radiation Oncology at Northwest Ohio Onocolgy Center, Maumee, Ohio, United States
🇺🇸
Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States
🇺🇸
Riverside Methodist Hospital, Columbus, Ohio, United States

and more 756 locations

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Completed

Conditions: Recurrent Squamous Cell Lung Carcinoma
Stage IV Squamous Cell Lung Carcinoma AJCC v7

Interventions: Drug: Erlotinib Hydrochloride
Biological: Durvalumab
Drug: Docetaxel
Drug: FGFR Inhibitor AZD4547
Biological: Ipilimumab
Other: Laboratory Biomarker Analysis
Drug: Palbociclib
Drug: Taselisib
Biological: Nivolumab
Biological: Rilotumumab
Other: Pharmacological Study
Drug: Talazoparib
Biological: Tremelimumab

First Posted Date: 2014-06-03

Last Posted Date: 2023-06-01

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 1864

Registration Number: NCT02154490

Locations: 🇺🇸
Riverside Methodist Hospital, Columbus, Ohio, United States
🇺🇸
Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸
Los Angeles County-USC Medical Center, Los Angeles, California, United States

and more 997 locations

S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer

Phase 3

Terminated

Conditions: Breast Cancer

Interventions: Drug: Fulvestrant
Drug: Placebo - Anastrozole
Drug: Everolimus
Drug: Anastrozole
Drug: Placebo - Everolimus

First Posted Date: 2014-05-14

Last Posted Date: 2021-01-28

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 37

Registration Number: NCT02137837

Locations: 🇺🇸
St. Patrick Hospital, Missoula, Montana, United States
🇺🇸
Southeastern Medical Oncology Center-Jacksonville, Jacksonville, North Carolina, United States
🇺🇸
Clackamas Radiation Oncology Center, Clackamas, Oregon, United States

and more 220 locations

S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib

Phase 2

Terminated

Conditions: Stage IV Non-small Cell Lung Cancer
Large Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Adenocarcinoma of the Lung

Interventions: Drug: pemetrexed disodium
Drug: crizotinib
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2014-05-09

Last Posted Date: 2020-02-20

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 1

Registration Number: NCT02134912

Locations: 🇺🇸
Sparrow Hospital, Lansing, Michigan, United States
🇺🇸
Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States
🇺🇸
Kootenai Cancer Center, Post Falls, Idaho, United States

and more 163 locations

S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer

Phase 1

Completed

Conditions: Metastatic Pancreatic Adenocarcinoma

Interventions: Drug: Oxaliplatin
Drug: PEGPH20
Drug: Leucovorin
Drug: Irinotecan
Drug: 5-fluorouracil

First Posted Date: 2013-10-09

Last Posted Date: 2024-02-09

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 126

Registration Number: NCT01959139

Locations: 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
UC Irvine Health Cancer Center-Newport, Costa Mesa, California, United States
🇺🇸
Palo Alto Medical Foundation-Camino Division, Mountain View, California, United States

and more 150 locations

S1204, Viral Screening in Newly Diagnosed Cancer Patients

Completed

Conditions: Cancer

First Posted Date: 2013-09-19

Last Posted Date: 2023-07-03

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 3051

Registration Number: NCT01946516

Locations: 🇺🇸
Louisiana State University Health Sciences Center Shreveport, Shreveport, Louisiana, United States
🇺🇸
Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States
🇺🇸
Greenville Health System Cancer Institute-Spartanburg, Spartanburg, South Carolina, United States

and more 55 locations

S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia

Phase 1

Completed

Conditions: B-cell Adult Acute Lymphoblastic Leukemia
Acute Leukemias of Ambiguous Lineage
Recurrent Adult Acute Lymphoblastic Leukemia
Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia
Recurrent Adult Burkitt Lymphoma

Interventions: Drug: cyclophosphamide
Drug: vincristine sulfate
Drug: prednisone
Biological: inotuzumab ozogamicin
Other: laboratory biomarker analysis

First Posted Date: 2013-08-19

Last Posted Date: 2023-05-03

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 50

Registration Number: NCT01925131

Locations: 🇺🇸
University of Rochester, Rochester, New York, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Stanford Cancer Institute Palo Alto, Palo Alto, California, United States

and more 2 locations

S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma

Phase 2

Completed

Conditions: Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions: Drug: Carfilzomib
Drug: Dexamethasone
Other: Laboratory Biomarker Analysis

First Posted Date: 2013-07-19

Last Posted Date: 2024-12-20

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 143

Registration Number: NCT01903811

Locations: 🇺🇸
Illinois CancerCare-Carthage, Carthage, Illinois, United States
🇺🇸
Illinois CancerCare-Princeton, Princeton, Illinois, United States
🇺🇸
John Muir Medical Center-Concord Campus, Concord, California, United States

and more 480 locations

S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

Phase 3

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: TAK-700
Drug: Bicalutamide

First Posted Date: 2013-03-13

Last Posted Date: 2025-03-19

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 1313

Registration Number: NCT01809691

Locations: 🇺🇸
Los Angeles County-USC Medical Center, Los Angeles, California, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

and more 555 locations

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

Phase 3

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: anastrozole
Drug: everolimus
Drug: exemestane
Drug: goserelin acetate
Drug: letrozole
Drug: leuprolide acetate
Drug: tamoxifen citrate
Other: placebo

First Posted Date: 2012-08-28

Last Posted Date: 2024-12-27

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 1939

Registration Number: NCT01674140

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Aria Health-Torresdale Campus, Philadelphia, Pennsylvania, United States
🇺🇸
Riverside Methodist Hospital, Columbus, Ohio, United States

and more 1445 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy